The effectiveness of vortioxetine in patients with depression in real clinical practice
https://doi.org/10.31363/2313-7053-2022-56-3-113-118
Abstract
The opinion article is devoted to the analysis of a large-scale 24-week multinational observational prospective cohort study «The effectiveness of vortioxetine in depression in real clinical practice» (BELIEVE). The study demonstrated the achievement of functional recovery of patients with depressive disorder when using vortioxetine, good efficacy and tolerability of the drug for the treatment of depression in a large and heterogeneous patient population representative of everyday psychiatric practice. A significant improvement in depressive and cognitive symptoms, productivity and quality of life of patients was achieved, while the greatest effect was observed when using vortioxetine as the first line of therapy. The results of the study confirmed the data of numerous RCTs devoted to the use of vortioxetine in the treatment of depressive disorder, and they can be used when choosing tactics of antidepressant therapy in conditions of routine psychiatric.
About the Author
N. N. Petrova
Saint Petersburg State University
Russian Federation
Russian Federation
Nataliia N. Petrova
St. Petersburg
References
1. Клинические рекомендации «Депрессивный эпизод, Рекуррентное депрессивное расстройство» [diseases.medelement.com]. diseases.medelement; 2021 [процитировано 3 сентября 2022]. Доступно: https://yandex.ru/search/?clid=2285101&text=september&lr=2
2. Kolbin A.S., Belousov D.Yu., Zyryanov S.K. et al. Issledovaniya real’noj klinicheskoj praktiki. Pod red. A.S. Kolbina. M.: Izdatel’stvo OKI: Buki Vedi, 2020. (In Russ.).
3. Martsevich SYu, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Efficacy of Drugs. Racional’naya Farmakoterapiya v Kardiologii. 2016;12(5):567-573. (In Russ). http//doi.org/10.20996/1819-6446-2016-12-5-567-573
4. Martsevich SYu, Lukina YuV, Kutishenko NP. Once again about the Hierarchy of Evidences in Medicine or whether it is Possible to Choose the Most Effective and Safe Drug with the Help of Observational Studies. Racional’naya Farmakoterapiya v Kardiologii. 2017;13(2):270-274. (In Russ.). http//doi.org/10.20996/1819-6446-2017-13-2-270-274
5. Petrova NN, Savitskaya KS. Diagnosis and therapy of comorbid anxiety and depressive disorders in clinical practice. Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva. 2021;1:92-102. (In Russ.). http//doi.org/10.31363/2313-7053-2021-1-3-1
6. Petrova NN, Palkin YuR, Faddeev DV, Zinovieva AG. Comorbidity of depressive and anxiety disorders in clinical practice. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2021;121(4): 31-37. (In Russ.).
7. Awad AG. ‘The patient’: at the center of patientreported outcomes. Expert Rev Pharmacoecon Outcomes Res. 2015;15:729–731. http//doi.org/10.1586/14737167.2015.1077118
8. Baldwin DS, Chrones L, Florea I et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016; 30:242–52. http//doi.org/10.1177/0269881116628440
9. Chen G, Højer AM, Areberg J et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686.
10. Chen G, Lee R, Højer AM et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–736.
11. Chen G, Nomikos GG, Affinito J et al. Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet. 2016;55(9):1115-1127.
12. Chin CN, Zain A, Hemrungrojn S et al. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin. 2018; 34:1975–84. http//doi.org/10.1080/03007995.2018.1477746
13. Chokka P, Bougie J, Proulx J et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.CNS Spectr. 2019;24:616–627. http//doi.org/10.1017/S1092852919000786
14. Chokka P, Ge H, Bougie J et al. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the At-WoRC study. Ther Adv Psychopharmacol. 2021; 11:20451253211013148. http//doi.org/10.1177/20451253211013148
15. Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study. J Occup Environ Med. 2020;62:e94–101. http//doi.org/10.1097/JOM.0000000000001805
16. Christensen MC, Wong CMJ, Baune BT. Symptoms of major depressive disorder and their impact on psychosocial functioning in the different phases of the disease: do the perspectives of patients and healthcare providers differ? Front Psychiatry. 2020;11:280. http//doi.org/10.3389/fpsyt.2020.00280
17. Christensen MC, Schmidt S, Grande I. The RECONNECT study: Effectiveness of vortioxetine (10–20 mg/day) in patients with major depressive disorder comorbid with generalized anxiety disorder. Poster presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress, Lisbon, Portugal, 2–5 October 2021.
18. Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021; 283:472–9. http//doi.org/10.1016/j.jad.2020.11.106
19. Galanopoulos A, Tsiolka E, Ntounas P et al. Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with MDD in Greece treated with vortioxetine: a patient-rated evaluation. Eur Psychiatry. 2021;64(1):334. http//doi.org/10.1192/j.eurpsy.2021.895
20. Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14:81–89. http//doi.org/10.1080/17460441.2019.1546691
21. Iovieno N, Papakostas GI, Feeney A et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021; 82:20r13682. http//doi.org/10.4088/JCP.20r13682
22. IsHak WW, James DM, Mirocha J et al. Patientreported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016; 7:160–169. http//doi.org/10.1177/2040622316639769
23. Kan K, Jörg F, Buskens E et al. Patients’ and clinicians’perspectives on relevant treatment outcomes in depression: qualitative study. BJPsych Open. 2020;6:e44. http//doi.org/10.1192/bjo.2020.27
24. Lam RW, Parikh SV,Michalak EE et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27:142–149.
25. Oluboka OJ, Katzman MA, Habert J et al. Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol. 2018;21:128–144. http//doi.org/10.1093/ijnp/pyx081
26. Salcedo B. The Comorbidity Of Anxiety And Depression.National Alliance on Mental Illness. 2018;19:325-333.
27. Saveanu R, Etkin A, Duchemin AM et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015; 61:1–12. http//doi.org/10.1016/j.jpsychires.2014.12.018
28. Sheehan DV, Nakagome K, Asami Y et al. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313. http//doi.org/10.1016/j.jad.2017.02.029
29. Wang G, Tan KHX, Ren H, Hammer-Helmich L. Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT Study.Neuropsychiatr Dis Treat. 2020;6:749–759. http//doi.org/10.2147/NDT.S230403
30. Yang YK, Chen CS, Tsai CFet al. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin. 2021;37:2163–2173. http//doi.org/10.1080/03007995.2021.1980869
Review
For citations:
Petrova N.N. The effectiveness of vortioxetine in patients with depression in real clinical practice. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2022;56(3):113-118. (In Russ.) https://doi.org/10.31363/2313-7053-2022-56-3-113-118
Views:
615
Email this article 